A citation-based method for searching scientific literature

Tingcun Zhao, Pratik Parikh, Siva Bhashyam, Hakki Bolukoglu, Indu Poornima, You-Tang Shen, Richard P Shannon. J Pharmacol Exp Ther 2006
Times Cited: 234







List of co-cited articles
1069 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion.
Lazaros A Nikolaidis, Sunil Mankad, George G Sokos, Glen Miske, Ankur Shah, Dariush Elahi, Richard P Shannon. Circulation 2004
654
43

Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy.
Lazaros A Nikolaidis, Dariush Elahi, Teresa Hentosz, Aaron Doverspike, Rhonda Huerbin, Lee Zourelias, Carol Stolarski, You-tang Shen, Richard P Shannon. Circulation 2004
390
41

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways.
Kiwon Ban, M Hossein Noyan-Ashraf, Judith Hoefer, Steffen-Sebastian Bolz, Daniel J Drucker, Mansoor Husain. Circulation 2008
752
41

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury.
Amal K Bose, Mihaela M Mocanu, Richard D Carr, Christian L Brand, Derek M Yellon. Diabetes 2005
459
40

Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury.
Leo Timmers, José P S Henriques, Dominique P V de Kleijn, J Hans Devries, Hans Kemperman, Paul Steendijk, Cees W J Verlaan, Marjolein Kerver, Jan J Piek, Pieter A Doevendans,[...]. J Am Coll Cardiol 2009
350
34

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice.
Mohammad Hossein Noyan-Ashraf, M Abdul Momen, Kiwon Ban, Al-Muktafi Sadi, Yu-Qing Zhou, Ali M Riazi, Laurie L Baggio, R Mark Henkelman, Mansoor Husain, Daniel J Drucker. Diabetes 2009
405
33

Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
Jacob Lønborg, Niels Vejlstrup, Henning Kelbæk, Hans Erik Bøtker, Won Yong Kim, Anders B Mathiasen, Erik Jørgensen, Steffen Helqvist, Kari Saunamäki, Peter Clemmensen,[...]. Eur Heart J 2012
387
31

Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure.
George G Sokos, Lazaros A Nikolaidis, Sunil Mankad, Dariush Elahi, Richard P Shannon. J Card Fail 2006
486
28

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
27

Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy.
Lazaros A Nikolaidis, Dariush Elahi, You-Tang Shen, Richard P Shannon. Am J Physiol Heart Circ Physiol 2005
209
24

Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy.
Siva Bhashyam, Anjali V Fields, Brandy Patterson, Jeffrey M Testani, Li Chen, You-Tang Shen, Richard P Shannon. Circ Heart Fail 2010
81
25

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.
Thomas Nyström, Mark K Gutniak, Qimin Zhang, Fan Zhang, Jens Juul Holst, Bo Ahrén, Ake Sjöholm. Am J Physiol Endocrinol Metab 2004
499
20


Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting.
George G Sokos, Hakki Bolukoglu, Judy German, Teresa Hentosz, George J Magovern, Thomas D Maher, David A Dean, Stephen H Bailey, Gary Marrone, Daniel H Benckart,[...]. Am J Cardiol 2007
191
19

Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat.
Indu Poornima, Suzanne B Brown, Siva Bhashyam, Pratik Parikh, Hakki Bolukoglu, Richard P Shannon. Circ Heart Fail 2008
144
18

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
18

Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Wei Ren Chen, Shun Ying Hu, Yun Dai Chen, Ying Zhang, Geng Qian, Jing Wang, Jun Jie Yang, Zhi Feng Wang, Feng Tian, Qing Xiu Ning. Am Heart J 2015
69
24

Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure.
Mads Halbirk, Helene Nørrelund, Niels Møller, Jens Juul Holst, Ole Schmitz, Roni Nielsen, Jens Erik Nielsen-Kudsk, Søren Steen Nielsen, Torsten Toftegaard Nielsen, Hans Eiskjaer,[...]. Am J Physiol Heart Circ Physiol 2010
119
16

Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
16


Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Marc A Pfeffer, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Lars V Køber, Francesca C Lawson, Lin Ping, Xiaodan Wei, Eldrin F Lewis,[...]. N Engl J Med 2015
15

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
15

Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats.
Ming Yu, Carol Moreno, Kimberly M Hoagland, Annette Dahly, Katie Ditter, Mahesh Mistry, Richard J Roman. J Hypertens 2003
221
14

The biology of incretin hormones.
Daniel J Drucker. Cell Metab 2006
13

Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia.
Jacob Lønborg, Henning Kelbæk, Niels Vejlstrup, Hans Erik Bøtker, Won Yong Kim, Lene Holmvang, Erik Jørgensen, Steffen Helqvist, Kari Saunamäki, Christian Juhl Terkelsen,[...]. Circ Cardiovasc Interv 2012
159
13

Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.
Louise E Robinson, Tim A Holt, Karen Rees, Harpal S Randeva, Joseph P O'Hare. BMJ Open 2013
199
13

A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans.
Philip A Read, Stephen P Hoole, Paul A White, Fakhar Z Khan, Michael O'Sullivan, Nick E J West, David P Dutka. Circ Cardiovasc Interv 2011
96
13

Cardiovascular biology of the incretin system.
John R Ussher, Daniel J Drucker. Endocr Rev 2012
371
13

Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
William B White, Christopher P Cannon, Simon R Heller, Steven E Nissen, Richard M Bergenstal, George L Bakris, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer,[...]. N Engl J Med 2013
13

GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.
Charles Pyke, R Scott Heller, Rikke K Kirk, Cathrine Ørskov, Steffen Reedtz-Runge, Peter Kaastrup, Anders Hvelplund, Linda Bardram, Dan Calatayud, Lotte Bjerre Knudsen. Endocrinology 2014
417
13

Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency.
Weike Bao, Karpagam Aravindhan, Hasan Alsaid, Thimmaiah Chendrimada, Matthew Szapacs, David R Citerone, Mark R Harpel, Robert N Willette, John J Lepore, Beat M Jucker. PLoS One 2011
69
17

GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure.
Minsuk Kim, Mathew J Platt, Tadao Shibasaki, Susan E Quaggin, Peter H Backx, Susumu Seino, Jeremy A Simpson, Daniel J Drucker. Nat Med 2013
306
12

Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure.
Que Liu, Christen Anderson, Anatoly Broyde, Clara Polizzi, Rayne Fernandez, Alain Baron, David G Parkes. Cardiovasc Diabetol 2010
92
13

Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism.
Weidong Chai, Zhenhua Dong, Nasui Wang, Wenhui Wang, Lijian Tao, Wenhong Cao, Zhenqi Liu. Diabetes 2012
130
12

Cardiac function in mice lacking the glucagon-like peptide-1 receptor.
Robert Gros, Xiaomang You, Laurie L Baggio, M Golam Kabir, Al Muktafi Sadi, Imran N Mungrue, Thomas G Parker, Qingling Huang, Daniel J Drucker, Mansoor Husain. Endocrinology 2003
146
12




GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice.
Naim Panjwani, Erin E Mulvihill, Christine Longuet, Bernardo Yusta, Jonathan E Campbell, Theodore J Brown, Catherine Streutker, Dianne Holland, Xiemin Cao, Laurie L Baggio,[...]. Endocrinology 2013
232
11

Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride.
Ananda Basu, Nisha Charkoudian, William Schrage, Robert A Rizza, Rita Basu, Michael J Joyner. Am J Physiol Endocrinol Metab 2007
175
11


Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents.
B B Dokken, L R La Bonte, G Davis-Gorman, M K Teachey, N Seaver, P F McDonagh. Horm Metab Res 2011
46
23

Cardiovascular actions of incretin-based therapies.
John R Ussher, Daniel J Drucker. Circ Res 2014
245
11


GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP.
Brian D Green, Katharine V Hand, Janette E Dougan, Bronagh M McDonnell, Roslyn S Cassidy, David J Grieve. Arch Biochem Biophys 2008
116
10


A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity.
Mohammad Hossein Noyan-Ashraf, Eric Akihiko Shikatani, Irmgard Schuiki, Ilya Mukovozov, Jun Wu, Ren-Ke Li, Allen Volchuk, Lisa Annette Robinson, Filio Billia, Daniel J Drucker,[...]. Circulation 2013
164
10

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
10


Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines.
Lazaros A Nikolaidis, Aaron Doverspike, Teresa Hentosz, Lee Zourelias, You-Tang Shen, Dariush Elahi, Richard P Shannon. J Pharmacol Exp Ther 2005
102
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.